Medicare Compliance & Reimbursement
You Have Representatives On Your Side In Cancer-Care Crisis
Oncologists, the House Ways & Means Health Subcommittee tried to make the Centers for Medicare & Medicaid Services (CMS) feel your pain in a July 13 hearing.
In the hearing, members of Congress tore into CMS Director Herb Kuhn and other officials over access to cancer drugs. "Our cancer care delivery system is facing a crisis," said Rep. Jim Ramstad (R-MN). He cited rising costs and a study by PricewaterhouseCoopers that found the government would slash cancer payments by $13 billion between 2004 and 2013. He accused Kuhn of reducing the oncology demonstration project from last year's levels and also asked why CMS wouldn't pay separately for treatment planning in cancer.
Kuhn replied that CMS used survey data on costs provided by oncologists to cover cancer administration. The AMA Relative Value Update Committee (RUC) didn't recommend paying separately for treatment planning, because it was covered in the evaluation and management codes, he added.
Kuhn also pointed out that drug administration fees had grown 117 percent in recent years, but Rep. Nancy Johnson (R-CT) said this was an increase in "a little, tiny fee." She asked why cancer care providers are seeing an overall decrease in their payments.
The add-on fee that doctors receive for administering drugs will expire at the end of the year and so will a demonstration project for oncology doctors. The American Society of Clinical Oncology called on Congress to extend the demonstration project, impose a payment floor on Part B drugs and exclude prompt-pay discounts from the calculation of manufacturer prices for drugs.
Subcommittee members also took CMS officials to task for access problems with intravenous immune globulin (IVIG). "If a severe immunodeficient patient doesn't get this drug, he will die," Rep. Jim McCrery (R-LA) scolded Kuhn.
CMS is waiting for more reports on whether patients have enough access to IVIG. CMS said besides raising fees for IVIG, the agency and the Food & Drug Administration was working with manufacturers on supply and regulatory issues. CMS also split the IVIG code into codes for liquid and powder IVIG at stakeholders' request, Kuhn pointed out.
CMS could pay for IVIG based on 95 percent of average wholesale price, the same as it now pays for blood and blood-derived products, McCrery suggested. However, Kuhn noted that Congress designated IVIG as not a blood-derived product in the Medicare Modernization Act.
To read all the testimony from the hearing, go to http://tinyurl.com/fppox.
Medicare Compliance & Reimbursement
- COVERAGE:
CMS Wants More Evidence To Fast-Track Coverage Determinations
Get ready for extensive documentation demands.
After the Centers for Medicare & Medicaid Services' (CMS) recent [...] - SUPPLIERS:
Prepare Yourself For Looming DME Quality Standards
Final version of standards due this month.
Expect a quality-standards wake up call this month if [...] - PHYSICIANS:
You May Not Have To Cope With DME Competitive Bidding
MedPAC tries to prevent competitive acquisition from becoming unreasonably restrictive.
The complicated system of competitive acquisition [...] - COMPETITIVE BIDDING:
Bidding Tailored Toward Conventional Suppliers
Therapists, docs lobby for exclusions.
Small suppliers of durable medical equipment, prosthetics, orthotics and supplies (DMEPOS)--led [...] - ONCOLOGISTS:
You Have Representatives On Your Side In Cancer-Care Crisis
CMS called on the carpet for IVIG, oncology access problems.
Oncologists, the House Ways & Means [...] - HEALTH PLANS:
How Medicare's New CDHP Frenzy Will Change The Marketplace
In addition to the new MSAs, Medicare benes can now have access to other HSA-like [...] - REIMBURSEMENT:
HHAs--Get Ready Now To Avoid Payment Hold Problems This Fall
Try these 5 tips to avert a cash-flow crunch during the mandated hold.
Now's the time [...] - INDUSTRY NOTES:
LTC Facilities May Need NPIs For Recertification Soon
Plus: Noridian gears up as new DME MAC in Jurisdiction D.
Long-term care providers' claims won't [...]
